Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Stinson

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Treatment and Research|January 29, 2000
Does reimbursement affect physician decision making?C L Bennett, T J Stinson
Cancer Investigation|February 7, 2001
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trialC L Bennett, T J Stinson
Toxicology and Applied Pharmacology|November 1, 1992
The relationship between nickel chloride-induced peroxidation and DNA strand breakage in rat liverT J Stinson, S Jaw, E H Jeffery, et al.
Seminars in Oncology|March 11, 1999
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancerC L Bennett, T J Stinson, T Yang, et al.
JAMA|October 27, 1999
Evaluation of conflict of interest in economic analyses of new drugs used in oncologyM Friedberg, B Saffran, T J Stinson, et al.
Cancer Investigation|December 11, 1999
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patientsT J Stinson, E Calhoun, T Yang, et al.
Medical and Pediatric Oncology|February 5, 2000
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trialsC L Bennett, T J Stinson, D Lane, et al.
Cancer Investigation|August 7, 2001
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trialC L Bennett, D Hynes, J Godwin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncologyK S Knox, J R Adams, B Djulbegovic, et al.
Bone Marrow Transplantation|October 21, 2000
Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantationT J Stinson, J R Adams, M R Bishop, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Treatment and Research|January 29, 2000
Does reimbursement affect physician decision making?C L Bennett, T J Stinson
Cancer Investigation|February 7, 2001
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trialC L Bennett, T J Stinson
Toxicology and Applied Pharmacology|November 1, 1992
The relationship between nickel chloride-induced peroxidation and DNA strand breakage in rat liverT J Stinson, S Jaw, E H Jeffery, et al.
Seminars in Oncology|March 11, 1999
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancerC L Bennett, T J Stinson, T Yang, et al.
JAMA|October 27, 1999
Evaluation of conflict of interest in economic analyses of new drugs used in oncologyM Friedberg, B Saffran, T J Stinson, et al.
Cancer Investigation|December 11, 1999
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patientsT J Stinson, E Calhoun, T Yang, et al.
Medical and Pediatric Oncology|February 5, 2000
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trialsC L Bennett, T J Stinson, D Lane, et al.
Cancer Investigation|August 7, 2001
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trialC L Bennett, D Hynes, J Godwin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncologyK S Knox, J R Adams, B Djulbegovic, et al.
Bone Marrow Transplantation|October 21, 2000
Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantationT J Stinson, J R Adams, M R Bishop, et al.
Pageof 2